UA99700C2 - Способ приготовления иммортализированной человеческой клеточной линии - Google Patents

Способ приготовления иммортализированной человеческой клеточной линии

Info

Publication number
UA99700C2
UA99700C2 UAA200801065A UAA200801065A UA99700C2 UA 99700 C2 UA99700 C2 UA 99700C2 UA A200801065 A UAA200801065 A UA A200801065A UA A200801065 A UAA200801065 A UA A200801065A UA 99700 C2 UA99700 C2 UA 99700C2
Authority
UA
Ukraine
Prior art keywords
cell line
serum
production
human cell
immortalized human
Prior art date
Application number
UAA200801065A
Other languages
English (en)
Ukrainian (uk)
Inventor
Карола Шрьодер
Кэтлин Вегманн
Хайан Динг
Original Assignee
Октафарма Биофармасьютикалз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99700(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Октафарма Биофармасьютикалз Гмбх filed Critical Октафарма Биофармасьютикалз Гмбх
Publication of UA99700C2 publication Critical patent/UA99700C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение относится к усовершенствованному способу приготовления иммортализированной человеческой клеточной линии, стойко трансформированной в бессывороточных условиях специфическим вектором, несущим ген, который кодирует заданный протеин. Кроме того, изобретение относится к клеточной линии, полученной с использованием указанного способа, способу получения заданного протеина с использованием указанной клеточной линии.
UAA200801065A 2005-06-30 2006-06-29 Способ приготовления иммортализированной человеческой клеточной линии UA99700C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105965A EP1739179A1 (en) 2005-06-30 2005-06-30 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Publications (1)

Publication Number Publication Date
UA99700C2 true UA99700C2 (ru) 2012-09-25

Family

ID=35427852

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200801065A UA99700C2 (ru) 2005-06-30 2006-06-29 Способ приготовления иммортализированной человеческой клеточной линии

Country Status (20)

Country Link
US (4) US8871439B2 (ru)
EP (2) EP1739179A1 (ru)
JP (3) JP5925407B2 (ru)
KR (1) KR101320489B1 (ru)
CN (2) CN101233238A (ru)
AU (1) AU2006265173B2 (ru)
BR (1) BRPI0613721B1 (ru)
CA (1) CA2611708C (ru)
DK (1) DK1896590T3 (ru)
ES (1) ES2574584T3 (ru)
HU (1) HUE028028T2 (ru)
IL (3) IL187676A (ru)
MX (1) MX2007015370A (ru)
NO (1) NO343221B1 (ru)
PL (1) PL1896590T3 (ru)
RU (1) RU2453597C2 (ru)
SI (1) SI1896590T1 (ru)
UA (1) UA99700C2 (ru)
WO (1) WO2007003582A2 (ru)
ZA (1) ZA200711013B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153366A2 (en) 2007-06-15 2008-12-18 Mogam Biotechnology Research Institute Method for manufacturing active recombinant blood coagulation factor ix
WO2009156430A1 (en) 2008-06-24 2009-12-30 Octapharma Ag A process of purifying coagulation factor viii
KR101921698B1 (ko) 2008-08-21 2018-11-26 옥타파마 아게 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
JP5592080B2 (ja) * 2009-05-08 2014-09-17 株式会社日立製作所 細胞培養方法、細胞培養システム
CN101906438B (zh) * 2009-06-05 2013-04-24 苏州泽璟生物制药有限公司 一种重组人凝血因子ⅶ在动物细胞内的表达和生产方法
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
DK2553095T3 (en) 2010-03-30 2017-01-23 Octapharma Ag PROCEDURE FOR CLEANING VITAMIN K-DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX
US9453045B2 (en) 2010-03-30 2016-09-27 Octapharma Ag Process for the purification of a growth factor protein
WO2011131720A1 (en) 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
EP2707387B1 (en) 2011-05-13 2019-12-25 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
CN103305540B (zh) * 2012-03-14 2015-03-25 齐鲁制药有限公司 一种用于生物学活性测定的质粒及其制备方法
WO2013166339A1 (en) 2012-05-02 2013-11-07 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
RU2731717C2 (ru) * 2013-05-03 2020-09-08 ФУДЖИФИЛМ ДИОСИНТ БАЙОТЕКНОЛОДЖИЗ ЮКей ЛИМИТЕД Способ экспрессии
JP6735672B2 (ja) 2013-09-12 2020-08-05 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第ｖｉｉｉ因子ベクター
CA2934705C (en) 2014-01-20 2020-03-31 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
CA2966527C (en) * 2014-11-02 2024-02-06 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
US20210124000A1 (en) 2018-05-04 2021-04-29 Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung eingetragener Verein Arterial spin labeling with evaluation of inversion state of magnetization
WO2020115318A1 (en) * 2018-12-06 2020-06-11 Basf Se Aqueous suspension comprising a zeolitic material and a zirconium chelate complex
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0150735B2 (en) 1984-01-12 2004-01-07 Chiron Corporation Protein composition exhibiting coagulation activity and method for the preparation thereof
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (fr) 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
DK155388C (da) 1986-07-08 1989-10-23 Palle Pedersen Laas
ATE63335T1 (de) 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
NO872932L (no) 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH084495B2 (ja) * 1988-08-19 1996-01-24 帝人株式会社 接着性動物細胞の培養方法
ZA909167B (en) 1989-11-17 1993-10-15 Chiron Corp Protein complexes having Factor VIII:C activity and production thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4204694C3 (de) 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
JPH08506498A (ja) 1993-02-09 1996-07-16 オクタファルマ・アクチエンゲセルシャフト 非脂質被覆ウイルスの失活方法
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
WO1999029848A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
ES2226383T3 (es) * 1998-04-17 2005-03-16 Societe Des Produits Nestle S.A. Linea de celulas inmortalizadas derivadas de tejidos cutaneos humanos normales.
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA2252972C (en) * 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
EP1010762A1 (en) 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
DE60043273D1 (de) 1999-04-15 2009-12-17 Crucell Holland Bv Verwendung von Rekombinanten Proteinen in Menschlichen Zellen
IL146128A0 (en) * 1999-04-29 2002-07-25 Leukotech As Expression of heparin-binding protein in recombinant mammalian cells
AU784506B2 (en) * 1999-08-25 2006-04-13 Immunex Corporation Compositions and methods for improved cell culture
IL151857A0 (en) 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
CN1443170A (zh) * 2000-07-20 2003-09-17 神经原公司 辣椒素受体配体
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
KR101149777B1 (ko) 2002-11-29 2012-06-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법
US7217566B2 (en) 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
CN104059147A (zh) * 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
JP2005073509A (ja) * 2003-08-28 2005-03-24 Nihon Pharmaceutical Co Ltd ヒトアンチトロンビンの生産方法
CA2540135C (en) * 2003-10-03 2012-12-04 Keiichi Fukuda Method of inducing the differentiation of stem cells into cardiomyocytes
EA200600918A1 (ru) * 2003-11-06 2006-10-27 Игзонхит Терапьютикс Са Васе455, вариант альтернативного сплайсинга бета-секретазы человека
WO2005045007A1 (ja) * 2003-11-06 2005-05-19 Kyoto University 幹細胞の凍結保存法およびシステム
WO2009101560A2 (en) 2008-02-15 2009-08-20 Koninklijke Philips Electronics N.V. Apparatus for segmenting an object comprising sub-objects

Also Published As

Publication number Publication date
KR101320489B1 (ko) 2013-10-30
CN105755041A (zh) 2016-07-13
NO20076087L (no) 2008-01-28
HUE028028T2 (en) 2016-11-28
US20150044720A1 (en) 2015-02-12
EP1739179A1 (en) 2007-01-03
RU2008103319A (ru) 2009-08-10
JP5925407B2 (ja) 2016-05-25
JP6754414B2 (ja) 2020-09-09
JP2016154537A (ja) 2016-09-01
US20160177362A1 (en) 2016-06-23
IL266122A (en) 2019-06-30
PL1896590T3 (pl) 2016-10-31
US9796986B2 (en) 2017-10-24
WO2007003582A3 (en) 2007-05-18
AU2006265173B2 (en) 2011-07-28
CA2611708C (en) 2019-11-12
US20170152523A1 (en) 2017-06-01
US8871439B2 (en) 2014-10-28
US9273325B2 (en) 2016-03-01
BRPI0613721B1 (pt) 2022-05-24
MX2007015370A (es) 2008-02-11
NO343221B1 (no) 2018-12-10
ZA200711013B (en) 2008-10-29
IL187676A0 (en) 2008-08-07
AU2006265173A1 (en) 2007-01-11
KR20080028891A (ko) 2008-04-02
CA2611708A1 (en) 2007-01-11
JP2019058173A (ja) 2019-04-18
SI1896590T1 (sl) 2016-07-29
BRPI0613721A2 (pt) 2011-02-08
IL250575A0 (en) 2017-03-30
ES2574584T3 (es) 2016-06-20
RU2453597C2 (ru) 2012-06-20
EP1896590B1 (en) 2016-03-23
DK1896590T3 (da) 2016-06-13
EP1896590A2 (en) 2008-03-12
JP2008544750A (ja) 2008-12-11
US9512457B2 (en) 2016-12-06
US20100184141A1 (en) 2010-07-22
IL187676A (en) 2017-02-28
WO2007003582A2 (en) 2007-01-11
CN101233238A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
UA99700C2 (ru) Способ приготовления иммортализированной человеческой клеточной линии
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
GB2441488A (en) Suspension culture of human embryonic stem cells
WO2008114673A1 (ja) ポリペプチドの製造方法
TW200716753A (en) Vector
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
PL1948789T3 (pl) Sposób wytwarzania ciągłych ludzkich linii komórkowych
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
MX2011006301A (es) Produccion de alcoholes de cadena ramificada por medio de microorganismos fotosinteticos.
AU2008301614A8 (en) Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same
MY185887A (en) Cell culture improvements
WO2010093954A3 (en) Control of plant stress tolerance, water use efficiency and gene expression using novel aba receptor proteins and synthetic agonists
WO2009120762A3 (en) Human cardiovascular progenitor cells
EP2516624A4 (en) CELL LINE 3M
CA2783820C (en) Protease variants
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
EP1963506A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE PRODUCTION OF RECOMBINANT GAMMA-CARBOXYLATED PROTEINS
UA105193C2 (ru) Вектор, содержащий две гомологические нуклеотидные последовательности
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
TW200740769A (en) Novel process
MX2011012623A (es) Construcciones de casb7439.
MX2009007790A (es) Mejora del crecimiento celular.
SG171481A1 (en) Hemopexin-like structure as polypeptide-scaffold
WO2012012271A3 (en) Novel glycosylated polypeptides